Results 1 to 10 of about 186,179 (282)

Current status of cytokine-induced killer cells and combination regimens in breast cancer [PDF]

Frontiers in Immunology
Breast cancer remains a significant health challenge worldwide, with substantial efforts aimed at understanding its pathogenesis, biological characteristics, and clinical triggers.
Yuancong Jiang, Jie Qiu, Nanwei Ye, Yingchun Xu   +3 more
doaj   +4 more sources

Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer [PDF]

Cell Communication and Signaling, 2022
Cytokine-induced killer (CIK) cell therapy is a type of adoptive immunotherapy that due to its high proliferation rate and anti-tumor characteristics, is being investigated to treat various solid tumors.
Farimah Fayyaz, Niloufar Yazdanpanah, Nima Rezaei   +2 more
doaj   +4 more sources

Cytokine-induced killer cells: new insights for therapy of hematologic malignancies [PDF]

Stem Cell Research & Therapy
Background Cytokine-induced killer (CIK) cells are a novel subgroup of immune effectors, classified as one of the modified T cell-mediated arms for immunotherapy.
Faezeh Ghanbari Sevari, Amir Mehdizadeh, Khadijeh Abbasi, Seyyed Sina Hejazian, Mortaza Raeisi   +4 more
doaj   +4 more sources

Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation [PDF]

Haematologica, 2010
Background Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood and has a poor prognosis. Here we assessed the capability of ex vivo expanded cytokine-induced killer cells to lyse both alveolar and embryonic rhabdomyosarcoma cell lines ...
Selim Kuçi, Eva Rettinger, Bernhard Voß, Gerrit Weber, Miriam Stais, Hermann Kreyenberg, Andre Willasch, Zyrafete Kuçi, Ewa Koscielniak, Stephan Klöss, Dorothee von Laer, Thomas Klingebiel, Peter Bader   +12 more
doaj   +3 more sources

How can Cytokine-induced killer cells overcome CAR-T cell limits [PDF]

Frontiers in Immunology, 2023
The successful treatment of patients affected by B-cell malignancies with Chimeric Antigen Receptor (CAR)-T cells represented a breakthrough in the field of adoptive cell therapy (ACT).
Elisa Cappuzzello, Emilia Vigolo, Giulia D’Accardio, Giuseppe Astori, Antonio Rosato, Antonio Rosato, Roberta Sommaggio, Roberta Sommaggio   +7 more
doaj   +2 more sources

Efficacy of modified dendritic cell–cytokine-induced killer cells loaded with tumour stem cell membrane microparticle therapy in the treatment of relapsed or refractory T- and NK-cell lymphoid proliferations and lymphomas: a report of three cases [PDF]

Annals of Hematology
The prognosis of relapsed or refractory T-cell and NK-cell lymphoid proliferations and lymphomas (R/R T/NK-LPD/LYM) remains poor. Modified dendritic cell–cytokine-induced killer (DC–CIK) cells loaded with tumour stem cell (TSC) membrane microparticles ...
Ao Wang, Tao Fan, Ju Zhang, Mei Ye, Hong Huang, Ze-Li Gao   +5 more
doaj   +2 more sources

Altered thymic differentiation and modulation of arthritis by invariant NKT cells expressing mutant ZAP70 [PDF]

Nature Communications, 2018
Invariant natural killer T (iNKT) cells can be subsetted based on their cytokine productions. Here the authors show, using Zap70 mutant mice, that interferon-γ secreting (IFN-γ) iNKT cells may be induced by hampered T cell receptor signallings to help ...
Meng Zhao, Mattias N. D. Svensson, Koen Venken, Ashu Chawla, Shu Liang, Isaac Engel, Piotr Mydel, Jeremy Day, Dirk Elewaut, Nunzio Bottini, Mitchell Kronenberg   +10 more
doaj   +5 more sources

Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials [PDF]

Journal of Translational Medicine
Background Immunotherapy utilizing dendritic cells (DCs) and cytokine-induced killer (CIK) cells is a promising treatment approach for solid tumors.
Wendi Jiang, Zhongda Wang, Qinghuizi Luo, Zhe Dai, Jialong Zhu, Xiaoyue Tao, Yiyang Xie, Yuanyang Du, Longwei Jiang, Xiaoyuan Chu, Gongbo Fu, Zengjie Lei   +11 more
doaj   +2 more sources

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma. [PDF]

Front Immunol
Moser LM, Heim C, Koschade SE, Wendel P, Bozkurt S, Harenkamp S, Kreyenberg H, Merker M, Münch C, Gradhand E, Vogler M, Ullrich E, Bönig H, Klusmann JH, Bader P, Wels WS, Rettinger E.   +16 more
europepmc   +2 more sources

Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma

Translational Oncology, 2022
Dendritic cells (DCs) are the most potent antigen-presenting cells, and have thus been used in clinical cancer vaccines. However, the effects of DC vaccines are still limited, leading researchers to explore novel ways to make them effective.
Tan-Huy Chu, Manh-Cuong Vo, Thangaraj Jaya Lakshmi, Seo-Yeon Ahn, Mihee Kim, Ga-Young Song, Deok-Hwan Yang, Jae-Sook Ahn, Hyeoung-Joon Kim, Sung-Hoon Jung, Je-Jung Lee   +10 more
doaj   +1 more source